智通财经APP获悉，百济神州(06160)涨超6%，截至发稿，涨6.04%，报158港元，成交额5.47亿港元。
消息面上，4月30日早间，百济神州公告，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics在‘803 专利授权后复审程序中受到公司质疑的‘803 专利的全部权利无效。Pharmacyclics可对USPTO的最终书面决定提起上诉。公司表示，百悦泽®是其原研药品，公司将对此类专利侵权指控进行坚决的辩护。
百济神2024年实现收入合计约38.1亿美元，同比增长约55%；产品收入同比增长约72.6%至约38亿美元。毛利约32.16亿美元，同比增长54.71%。公司全年业绩取得强劲增长，充分彰显了公司作为全球肿瘤治疗领导者的实力。这得益于百悦泽®的持续成功以及公司在肿瘤领域开发的最丰富的实体瘤管线之一，预计2025年将有多个项目进行数据读出。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.